Every Form 4 that INTERPACE BIOSCIENCES INC (IDXG) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IDXG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IDXG filings page.
INTERPACE BIOSCIENCES, INC. (IDXG) reported equity compensation and related share movements for CEO, President & Chairman Thomas W. Burnell. On August 20, 2026 he was granted 1,966,763 Restricted Stock Units (RSUs), each representing one share of common stock, all of which vested upon grant and included additional RSUs intended to cover tax obligations. These RSUs converted into common stock, and 581,718 shares were returned to the company to satisfy tax withholding obligations, with Burnell receiving the remaining shares. He also received a grant of 554,018 stock options with a strike price of $2.02 per share, vesting in four equal annual installments beginning August 20, 2027 and expiring August 20, 2036. Separately, 10,885 shares of common stock are reported as held indirectly by his spouse.
INTERPACE BIOSCIENCES, INC. (symbol: IDXG) is the issuer of record for a Form 4 filing submitted to the SEC.
INTERPACE BIOSCIENCES, INC. (symbol: IDXG) is the issuer of record for a Form 4 filing submitted to the SEC.
INTERPACE BIOSCIENCES, INC. (symbol: IDXG) is the issuer of record for a Form 4 filing submitted to the SEC.
INTERPACE BIOSCIENCES, INC. (symbol: IDXG) is the issuer of record for a Form 4 filing submitted to the SEC.
INTERPACE BIOSCIENCES, INC. (IDXG) reported equity compensation transactions for CFO & COO Christopher McCarthy on August 20, 2026. He was granted 554,018 RSUs, of which 277,009 vested immediately and converted into common stock, with 277,009 RSUs scheduled to vest on August 20, 2027, subject to continued service. He also received a stock option for 277,009 shares of common stock at an exercise price of $2.02 per share, expiring August 20, 2036, vesting in four equal annual installments beginning August 20, 2027. After these transactions, he directly held 323,800 shares of common stock.
1315 Capital II, L.P. reported acquisition or exercise transactions in a Form 4 filing for IDXG. The filing lists transactions totaling 9,424,941 shares at a weighted average price of $2.02 per share. Following the reported transactions, holdings were 9,405,941 shares.
Ampersand 2018 Limited Partnership, a 10% owner of Interpace Biosciences, Inc., reported converting preferred stock into common shares. On January 20, 2026, it converted 28,000 Series C Convertible Preferred shares into 13,861,386 shares of common stock.
The preferred shares had a stated value of $1,000 per share and a conversion price of $2.02 per common share, which determines how many common shares are issued on conversion. Following this transaction, the reporting holder owned 13,861,386 common shares directly and no remaining Series C preferred shares.